Scarica l'app Stockscreener
98.33
3.12%
-3.17
Dopo l'orario di chiusura:
98.33
Precedente Chiudi:
$101.50
Aprire:
$100.58
Volume 24 ore:
613.60K
Relative Volume:
0.48
Capitalizzazione di mercato:
$8.54B
Reddito:
$688.00K
Utile/perdita netta:
$-168.74M
Rapporto P/E:
-41.71
EPS:
-2.3577
Flusso di cassa netto:
$-185.87M
1 W Prestazione:
-3.72%
1M Prestazione:
+10.76%
6M Prestazione:
+207.47%
1 anno Prestazione:
+479.43%
Intervallo 1D:
$95.27
$100.58
Intervallo di 1 settimana:
$92.37
$105.05
Portata 52W:
$14.51
$105.09
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
98.33 | 8.69B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | Raymond James | Strong Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Wolfe Research downgrades Spyre stock rating on valuation concerns By Investing.com - Investing.com Canada
SYRE|Spyre Therapeutics Inc|Price:99.950|Chg%:-2.180 - TradingKey
Spyre Therapeutics Inc (SYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Spyre Therapeutics Inc (SYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spyre Therapeutics Inc (SYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spyre Therapeutics Market Sentiment - Benzinga España
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Inc (SYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ETFs Investing in Spyre Therapeutics, Inc Stocks - TradingView
Spyre Therapeutics, Inc. earns Great Place to Work certification for 2026 - Traders Union
SYRE Stock Draws Analyst Upgrades As Volatility Spikes - StocksToTrade
Why Spyre Therapeutics (SYRE) Stock Is Up Today - Moomoo
Spyre Therapeutics stock hits 52-week high at 102.46 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock hits 52-week high at 102.46 USD - Investing.com
Spyre Therapeutics (SYRE) Slides 4.1% as Biotech Sector Faces HeadwindsIchimoku Cloud - dars.gov.et
Mizuho raises Spyre stock price target to $120 on IBD data - Investing.com UK
Spyre Therapeutics, Inc. participates in key Boston investor event - Traders Union
Mizuho raises Spyre stock price target to $120 on IBD data By Investing.com - Investing.com South Africa
SYRE Maintained by Mizuho -- Price Target Raised to $120 - GuruFocus
Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating - marketscreener.com
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $119 - Moomoo
Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing - Moomoo
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Price to sales forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
Price to book forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding? - simplywall.st
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $119 - Moomoo
Spyre Therapeutics Inc. (SYRE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Spyre Therapeutics (SYRE) Draws Bullish Targets Amid Volatile Trading - StocksToTrade
Spyre falls after $2M insider sale - MSN
Spyre Therapeutics (SYRE) Study result Summary - Quartr
Spyre Therapeutics (SYRE) Leerink Global Healthcare Conference 2026 Summary - Quartr
Spyre Therapeutics stock hits 52-week high at 51.08 USD - Investing.com
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative - Sahm
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock By Investing.com - Investing.com India
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares By Investing.com - Investing.com India
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock - Investing.com
Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares - Investing.com
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares - Investing.com Nigeria
Form 144 SPYRE THERAPEUTICS INC For: 1 July By Investing.com - Investing.com Canada
Form 144 | Spyre Therapeutics(SYRE.US) Director Proposes to Sell 4 Million in Common Stocks - Moomoo
SYRE (NASDAQ) Form 144: Insider sales and 45,000-share notice - Stock Titan
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spyre Therapeutics Inc Azioni (SYRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Burrows Scott L | Chief Financial Officer |
Jul 01 '26 |
Sale |
87.74 |
7,500 |
658,040 |
97,994 |
| Sloan Sheldon | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
27.46 |
8,334 |
228,852 |
8,334 |
| Sloan Sheldon | Chief Medical Officer |
Jul 01 '26 |
Sale |
87.70 |
8,334 |
730,896 |
0 |
| Turtle Cameron | Chief Executive Officer |
Jul 01 '26 |
Sale |
87.69 |
15,000 |
1,315,346 |
582,540 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):